US Patent

US10851377 — Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder

Method of Use · Assigned to Alnylam Pharmaceuticals Inc · Expires 2036-08-25 · 10y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using RNAi agents to inhibit PCSK9 gene expression and treat lipid disorders such as hyperlipidemia.

USPTO Abstract

The invention relates to methods of inhibiting the expression of a PCSK9 gene in a subject, as well as therapeutic and prophylactic methods for treating subjects having a lipid disorder, such as a hyperlipidemia using RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene.

Drugs covered by this patent

inclisiran-sodium (INCLISIRAN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4413`	—	inclisiran-sodium

Patent Metadata

Patent number: US10851377
Jurisdiction: US
Classification: Method of Use
Expires: 2036-08-25
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.